Comprehensive characterization of the Published Kinase Inhibitor Set

Nature Biotechnology

Volumn 34, Issue 1, 2016, Pages 95-103

  Elkins, Jonathan M ^a   Fedele, Vita ^a   Szklarz, Marta ^a   Abdul Azeez, Kamal R ^a   Salah, Eidarus ^a   Mikolajczyk, Jowita ^b,m   Romanov, Sergei ^b   Sepetov, Nikolai ^b   Huang, Xi Ping ^c   Roth, Bryan L ^c   Al Haj Zen, Ayman ^d   Fourches, Denis ^e,m,n   Muratov, Eugene ^e   Tropsha, Alex ^e   Morris, Joel ^f   Teicher, Beverly A ^f   Kunkel, Mark ^f   Polley, Eric ^f   Lackey, Karen E ^g   Atkinson, Francis L ^h   Overington, John P ^h,m,o   Bamborough, Paul ⁱ   Müller, Susanne ^a   Price, Daniel J ^j   Willson, Timothy M ^e,j,m   Drewry, David H ^j,m,p   Knapp, Stefan ^a,k,l   Zuercher, William J ^e,j,m   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Nanosyn Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e University of North Carolina   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GLAXOSMITHKLINE   (United States)

^k GOETHE UNIVERSITY   (Germany)

^l Buchmann Institute for Molecular Life Sciences   (Germany)

^m Novartis Vaccines and Diagnostics   (United States)

ⁿ NORTH CAROLINA STATE UNIVERSITY   (United States)

^o Stratified Medical   (United Kingdom)

^p Meryx Pharmaceuticals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; CELLS; DISEASES; ENZYME INHIBITION; PROTEINS; RECOMBINANT PROTEINS;

CANCER CELL GROWTH; CELLULAR ASSAYS; CHEMICAL PROBES; G PROTEIN COUPLED RECEPTORS; KINASE INHIBITORS; PROTEIN KINASE INHIBITORS; SELECTIVE INHIBITORS; TARGET VALIDATIONS;

ENZYMES;

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; GSK 1007102B; GSK 204925; GSK 204925A; GSK 238583A; GSK 3012825A; GSK 317314A; GSK 711701A; GW 440139A; GW 559768X; GW 583373A; GW 682841X; GW 779439X; LAPATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RECOMBINANT ENZYME; SB 404243; SB 437013; SB 518304AAA; SB 590885AAD; SB 633825; SB 636396AAA; SB 739245AC; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; PHOSPHOTRANSFERASE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG SCREENING; ENZYME INHIBITION; IC50; IN VITRO STUDY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; ANTAGONISTS AND INHIBITORS; GLYCOSYLATION;

GLYCOSYLATION; PHOSPHOTRANSFERASES; PROTEIN KINASE INHIBITORS;

EID: 84953774679     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3374     Document Type: Conference Paper

References (54)

1. Bamborough, P. System-based drug discovery within the human kinome. Expert Opin. Drug Discov. 7, 1053-1070 (2012).
2. Cohen, P. & Alessi, D.R. Kinase drug discovery - what's next in the field? ACS Chem. Biol. 8, 96-104 (2013).
3. Wu, P., Nielsen, T.E. & Clausen, M.H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36, 422-439 (2015).
4. Fedorov, O., Müller, S. & Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166-169 (2010).
5. Edwards, A.M., Bountra, C., Kerr, D.J. & Willson, T.M. Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol. 5, 436-440 (2009).
6. Drewry, D.H., Willson, T.M. & Zuercher, W.J. Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS). Curr. Top. Med. Chem. 14, 340-342 (2014).
7. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
8. Fedorov, O., Niesen, F.H. & Knapp, S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol. Biol. 795, 109-118 (2012).
9. Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914 (2008).
10. Witherington, J. et al. 5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 13, 1581-1584 (2003).
11. Conway, J.G. et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. USA 102, 16078-16083 (2005).
12. Takle, A.K. et al. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett. 16, 378-381 (2006).
13. Workman, P. & Collins, I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17, 561-577 (2010).
14. Jester, B.W. et al. A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J. Am. Chem. Soc. 132, 11727-11735 (2010).
15. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006).
16. Ciceri, P. et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305-312 (2014).
17. Huber, K.V. et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508, 222-227 (2014).
18. Fourches, D. & Tropsha, A. Using graph indices for the analysis and comparison of chemical datasets. Mol. Inform. 32, 827-842 (2013).
19. Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
20. Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
21. Reinhold, W.C. et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499-3511 (2012).
22. Miyazaki, Y. et al. Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg. Med. Chem. Lett. 17, 1773-1778 (2007).
23. Ardini, E. et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495-1507 (2014).
24. Hasegawa, M. et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J. Med. Chem. 50, 4453-4470 (2007).
25. Belkina, N.V., Liu, Y., Hao, J.J., Karasuyama, H. & Shaw, S. LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. Proc. Natl. Acad. Sci. USA 106, 4707-4712 (2009).
26. Kuramochi, S. et al. LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes. J. Biol. Chem. 272, 22679-22684 (1997).
27. Viswanatha, R., Ohouo, P.Y., Smolka, M.B. & Bretscher, A. Local phosphocycling mediated by LOK/SLK restricts ezrin function to the apical aspect of epithelial cells. J. Cell Biol. 199, 969-984 (2012).
28. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007).
29. Arnaoutova, I. & Kleinman, H.K. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat. Protoc. 5, 628-635 (2010).
30. Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734-745 (2007).
31. Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844 (2006).
32. Olsson, A.K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371 (2006).
33. Verheul, H.M. & Pinedo, H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7, 475-485 (2007).
34. Gao, Y. et al. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J. 451, 313-328 (2013).
35. Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H. & Peterson, J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
36. Davis, M.I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
37. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
38. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
39. Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
40. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
41. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
42. Metz, J.T. et al. Navigating the kinome. Nat. Chem. Biol. 7, 200-202 (2011).
43. Posy, S.L. et al. Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54-66 (2011).
44. Dranchak, P. et al. Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays. PLoS One 8, e57888 (2013).
45. Atkinson, J.M. et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20, 384-399 (2011).
46. Ember, S.W. et al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 9, 1160-1171 (2014).
47. Guo, K., Shelat, A.A., Guy, R.K. & Kastan, M.B. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. J. Biomol. Screen. 19, 538-546 (2014).
48. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
49. Haystead, T.A. The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117-1127 (2006).
50. Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215-220 (2012).
51. 2B receptor agonists: implications for drug safety assessment. Mol. Pharmacol. 76, 710-722 (2009).
52. Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615-619 (2013).
53. Holbeck, S.L., Collins, J.M. & Doroshow, J.H. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol. Cancer Ther. 9, 1451-1460 (2010).
54. Boutros, M., Brás, L.P. & Huber, W. Analysis of cell-based RNAi screens. Genome Biol. 7, R66 (2006).